FORM 9

NOTICE OF PROPOSED ISSUANCE OF LISTED SECURITIES

(or securities convertible or exchangeable into listed securities)

Please complete the following:

Name of Listed Issuer: NanoSphere Health Sciences Inc. (the “Issuer”).

Trading Symbol: NSHS .

Date: Feb. 20, 2019 .

Is this an updating or amending Notice: 🗹 Yes 🞎 No

If yes provide date(s) of prior Notices: May 24, 2018 .

Issued and Outstanding Securities of Issuer Prior to Issuance: 101,567,332 .

Date of News Release Announcing Private Placement: May 24, 2018 .

Closing Market Price on Day Preceding the Issuance of the News Release: $0.47 .

**1. Private Placement (if shares are being issued in connection with an acquisition (either as consideration or to raise funds for a cash acquisition), proceed to Part 2 of this form)**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Full Name & Residential Address of Placee** | **Number of Securities Purchased or to be Purchased** | **Purchase price per Security (CDN$)** | **Conversion****Price (if****applicable)** | **Prospectus Exemption** | **No. of Securities, directly or indirectly, Owned, Controlled or Directed** | **Payment Date (1)** | **Describe relation-ship to Issuer (2)** |
|  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |

1. Indicate date each placee advanced or is expected to advance payment for securities. Provide details of expected payment date, conditions to release of funds etc. Indicate if the placement funds been placed in trust pending receipt of all necessary approvals.
2. Indicate if Related Person.

1An issuance of non-convertible debt does not have to be reported unless it is a significant transaction as defined in Policy 7, in which case it is to be reported on Form 10.

1. Total amount of funds to be raised: .

2. Provide full details of the use of the proceeds. The disclosure should be sufficiently complete to enable a reader to appreciate the significance of the transaction without reference to any other material: .

1. Provide particulars of any proceeds which are to be paid to Related Persons of the Issuer: .
2. If securities are issued in forgiveness of indebtedness, provide details and attach the debt agreement(s) or other documentation evidencing the debt and the agreement to exchange the debt for securities.
3. Description of securities to be issued:

 (a) Class: .

 (b) Number: .

 (c) Price per security: .

 (d) Voting rights:

1. Provide the following information if Warrants, (options) or other convertible securities are to be issued:

 (a) Number: .

1. Number of securities eligible to be purchased on exercise of Warrants (or options): .

 (c) Exercise price: .

 (d) Expiry date: .

## Provide the following information if debt securities are to be issued:

 (a) Aggregate principal amount: .

 (b) Maturity date: .

 (c) Interest rate: .

 (d) Conversion terms: .

 (e) Default provisions: .

1. Provide the following information for any agent’s fee, commission, bonus or finder’s fee, or other compensation paid or to be paid in connection with the placement (including warrants, options, etc.):

(a) Details of any dealer, agent, broker or other person receiving compensation in connection with the placement (name, address. If a corporation, identify persons owning or exercising voting control over 20% or more of the voting shares if known to the Issuer): .

(b) Cash: .

(c) Securities: .

(d) Other: .

(e) Expiry date of any options, warrants etc.: .

(f) Exercise price of any options, warrants etc.: .

1. State whether the sales agent, broker, dealer or other person receiving compensation in connection with the placement is Related Person or has any other relationship with the Issuer and provide details of the relationship:

 .

1. Describe any unusual particulars of the transaction (i.e. tax “flow through” shares, etc.):

 .

1. State whether the private placement will result in a change of control:

 .

1. Where there is a change in the control of the Issuer resulting from the issuance of the private placement shares, indicate the names of the new controlling shareholders: .
2. Each purchaser has been advised of the applicable securities legislation restricted or seasoning period. All certificates for securities issued which are subject to a hold period bear the appropriate legend restricting their transfer until the expiry of the applicable hold period required by National Instrument 45-102.

**2. Acquisition**

1. Provide details of the assets to be acquired by the Issuer (including the location of the assets, if applicable). The disclosure should be sufficiently complete to enable a reader to appreciate the significance of the transaction without reference to any other material:

Corporate and financial advice and services with respect to business opportunities and developing a capital markets strategy, including: financial and operational analysis of the Issuer; sourcing and reviewing strategic opportunities and synergies; advising on potential mergers & acquisitions and sources of funding; research coverage and outreach initiatives; providing capital market intelligence; marketing to investors, analysts and broker dealers; introductions to strategic investors.

1. Provide details of the acquisition including the date, parties to and type of agreement (eg. sale, option, license etc.) and relationship to the Issuer. The disclosure should be sufficiently complete to enable a reader to appreciate the significance of the acquisition without reference to any other material:

Corporate and financial advisory services letter agreement dated May 20, 2018, between the Issuer and Gravitas Securities Inc. (“Gravitas”). Gravitas is at arms-length to the Issuer.

1. Provide the following information in relation to the total consideration for the acquisition (including details of all cash, securities or other consideration) and any required work commitments:
2. Total aggregate consideration in Canadian dollars: $15,000 per month payable in cash and common shares over a term of 12 months subject to earlier termination; plus $2,500 per month research fee payable in cash over 12 months.
3. Cash: Month 1: $2,500; Months 2-5: $10,000 per month;
Month 6: $17,500; and Months 7-12: $10,000 per month.
4. Securities (including options, warrants etc.) and dollar value:

(i) Common shares having a value of – for Month 1: $15,000; for Months 2-5: $7,500 per month; for Month 6: nil; for Months 7-12: 7,500 per month; and (ii) 965,555 options exercisable at $0.65 until May 24, 2023.

1. Other: .
2. Expiry date of options, warrants, etc. if any: see para (c) .
3. Exercise price of options, warrants, etc. if any: see para (c) .
4. Work commitments: .
5. State how the purchase or sale price was determined (e.g. arm’s-length negotiation, independent committee of the Board, third party valuation etc).

Arm’s length negotiation .

1. Provide details of any appraisal or valuation of the subject of the acquisition known to management of the Issuer: n/a .
2. The names of parties receiving securities of the Issuer pursuant to the acquisition and the number of securities to be issued are described as follows:

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Name of Party(If not an individual, name all insiders of the Party)** | **Number and Type of Securities to be Issued** | **Dollar value per Security (CDN$)** | **Conversion price (if applicable)** | **Prospectus Exemption** | **No. of Securities, directly or indirectly, Owned, Controlled or Directed by Party** | **Describe relationship to Issuer (1)** |
| Gravitas Securities Inc. | 35,022common shares(2) | 0.428 | n/a | NI45-106 section 2.3 | nil | arm’s length |
|  | 19,333common shares(3) | 0.388 | n/a | NI45-106 section 2.3 | nil | arm’s length |
|  | 19,455common shares(4) | 0.386 | n/a | NI45-106 section 2.3 | nil | arm’s length |
|  | 17,401common shares(5) | 0.431 | n/a | NI45-106 section 2.3 | nil | arm’s length |
|  | 18,750common shares(6) | 0.40 | n/a | NI45-106 section 2.3 | nil | arm’s length |
|  | 11,364common shares(7) | 0.33 | n/a | NI45-106 section 2.3 | nil | arm’s length |

1. Indicate if Related Person
2. Share payment for Month 1 (May 22 – June 21); see paragraph 3(c).
3. Share payment for Month 2 (June 22 – July 21); see paragraph 3(c).
4. Share payment for Month 3 (July 22 – Aug 21); see paragraph 3(c).
5. Share payment for Month 4 (Aug 22 – Sept 21); see paragraph 3(c).
6. Share payment for Month 5 (Sept 22 – Oct 21); see paragraph 3(c).
7. Share payment for Month 6 (Oct 22 – Nov 21); see paragraph 3(c).
8. Details of the steps taken by the Issuer to ensure that the vendor has good title to the assets being acquired: n/a .
9. Provide the following information for any agent’s fee, commission, bonus or finder’s fee, or other compensation paid or to be paid in connection with the acquisition (including warrants, options, etc.):

(a) Details of any dealer, agent, broker or other person receiving compensation in connection with the acquisition (name, address. If a corporation, identify persons owning or exercising voting control over 20% or more of the voting shares if known to the Issuer):

(b) Cash: .

(c) Securities: .

(d) Other: .

1. Expiry date of any options, warrants etc.: .
2. Exercise price of any options, warrants etc.: .
3. State whether the sales agent, broker or other person receiving compensation in connection with the acquisition is a Related Person or has any other relationship with the Issuer and provide details of the relationship. .
4. If applicable, indicate whether the acquisition is the acquisition of an interest in property contiguous to or otherwise related to any other asset acquired in the last 12 months: n/a .

**Certificate Of Compliance**

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance on behalf of the Issuer.

1. As of the date hereof there is not material information concerning the Issuer which has not been publicly disclosed.
2. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CSE Policy 1).
3. All of the information in this Form 9 Notice of Issuance of Securities is true.

Dated February 20, 2019 .

 Robert Sutton
Name of Director or Senior Officer

 *“Robert Sutton”*
Signature

 CEO
Official Capacity